Answers are grounded in this paper and cite their sources.
Sleeve gastrectomy (SG) is an effective surgical treatment for severe obesity but is associated with bone mineral density (BMD) loss. This analysis investigates postoperative bisphosphonate effects on computed tomography (CT)-derived compartmental volumetric BMD (vBMD) and associations with CT-derived muscle outcomes. The 6-month pilot study randomized 24 SG patients to once-monthly 150 mg risedronate (n = 11) or placebo (n = 13). CT scans were collected at baseline, and 6- and 12-months postoperatively to assess hip and spine vBMD. Treatment effects were estimated using a mixed linear model adjusted for sex and baseline measures, and Pearson correlations with CT-derived muscle outcomes were assessed. There were no significant vBMD differences between risedronate vs. placebo groups after SG, but 6-month trends suggest vBMD losses [mg/cm 3 ] with risedronate were potentially attenuated in the trabecular compartment of the total hip [− 8.8 vs. − 9.6], femoral neck [− 3.6 vs. − 7.3], and L1–L4 vertebrae [− 8.4 vs. − 11.1]. Muscle–bone correlations were not significant but trends suggest larger and less fat infiltrated trunk muscles may protect against spine vBMD loss. This pilot study did not find a significant treatment effect of risedronate on vBMD in SG patients, but exploratory findings in relation with muscle measures warrant additional investigation in a larger study.
No takes yet. Share an insight, caveat, or question.
Greene et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: